Ignyte Acquisition Corp
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company's lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an… Read more
Ignyte Acquisition Corp (PKBO) - Net Assets
Latest net assets as of September 2024: $-20.91 Million USD
Based on the latest financial reports, Ignyte Acquisition Corp (PKBO) has net assets worth $-20.91 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.64 Million) and total liabilities ($22.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-20.91 Million |
| % of Total Assets | -1278.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Ignyte Acquisition Corp - Net Assets Trend (2020–2023)
This chart illustrates how Ignyte Acquisition Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ignyte Acquisition Corp (2020–2023)
The table below shows the annual net assets of Ignyte Acquisition Corp from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-18.16 Million | -124.31% |
| 2022-12-31 | $-8.09 Million | -318.26% |
| 2021-12-31 | $-1.94 Million | -19181.68% |
| 2020-12-31 | $10.14K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ignyte Acquisition Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3816671199.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $20.01 Million | % |
| Total Equity | $-18.16 Million | 100.00% |
Ignyte Acquisition Corp Competitors by Market Cap
The table below lists competitors of Ignyte Acquisition Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sydinv Formue Vækstori Akk A
CO:SYVFVOAKKA
|
$225.43K |
|
Jyske In Fjernøsten Akt SRI KL
CO:JYIFJASRIKL
|
$225.65K |
|
WaterBridge Infrastructure LLC
NYSE:WBI
|
$225.70K |
|
Latitude Tree Holdings Bhd
KLSE:7006
|
$225.77K |
|
HRES11
SA:HRES11
|
$225.32K |
|
MANPOWER (MPW.SG)
STU:MPW
|
$225.28K |
|
HHLA N (HHFA.SG)
STU:HHFA
|
$225.14K |
|
Brenmiller Energy Ltd Ordinary Shares
NASDAQ:BNRG
|
$225.12K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ignyte Acquisition Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -8,094,477 to -18,156,949, a change of -10,062,472.
- Net loss of 12,825,917 reduced equity.
- New share issuances of 105,317 increased equity.
- Other comprehensive income decreased equity by 29,518.
- Other factors increased equity by 2,687,646.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.83 Million | -70.64% |
| Share Issuances | $105.32K | +0.58% |
| Other Comprehensive Income | $-29.52K | -0.16% |
| Other Changes | $2.69 Million | +14.8% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Ignyte Acquisition Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $0.02 | x |
| 2021-12-31 | $-0.11 | $0.02 | x |
| 2022-12-31 | $-0.46 | $0.02 | x |
| 2023-12-31 | $-0.79 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ignyte Acquisition Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-6.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -24.24% | 0.00% | 0.00x | 1.02x | $-3.47K |
| 2021 | 0.00% | -1569.65% | 0.49x | 0.00x | $-8.10 Million |
| 2022 | 0.00% | -2153.88% | 0.08x | 0.00x | $-12.28 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.01 Million |
Industry Comparison
This section compares Ignyte Acquisition Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ignyte Acquisition Corp (PKBO) | $-20.91 Million | -24.24% | N/A | $225.35K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |